Published in J Am Soc Nephrol on March 01, 2004
Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes (2011) 2.03
p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels. BMC Nephrol (2007) 1.11
Glucosamine induces cell-cycle arrest and hypertrophy of mesangial cells: implication of gangliosides. Biochem J (2005) 0.93
Silencing of sodium-hydrogen exchanger 1 attenuates the proliferation, hypertrophy, and migration of pulmonary artery smooth muscle cells via E2F1. Am J Respir Cell Mol Biol (2011) 0.92
Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Mol Cancer (2007) 0.91
Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53. J Urol (2008) 0.89
CDK inhibitor p21 is prosurvival in adriamycin-induced podocyte injury, in vitro and in vivo. Am J Physiol Renal Physiol (2010) 0.88
Effects of protein type and composition on postprandial markers of skeletal muscle anabolism, adipose tissue lipolysis, and hypothalamic gene expression. J Int Soc Sports Nutr (2015) 0.81
Involvement of Histone Lysine Methylation in p21 Gene Expression in Rat Kidney In Vivo and Rat Mesangial Cells In Vitro under Diabetic Conditions. J Diabetes Res (2016) 0.81
Not just an inhibitor: a role for p21 beyond the cell cycle-"The truth is rarely pure and never simple". J Am Soc Nephrol (2004) 0.77
Histone Lysine Methylation in TGF-β1 Mediated p21 Gene Expression in Rat Mesangial Cells. Biomed Res Int (2016) 0.77
Effects of oral phosphatidic acid feeding with or without whey protein on muscle protein synthesis and anabolic signaling in rodent skeletal muscle. J Int Soc Sports Nutr (2015) 0.76
A comprehensive urinary metabolomic approach for identifying kidney cancerr. Anal Biochem (2007) 3.14
CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol (2012) 2.05
Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res (2012) 1.81
Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics (2008) 1.78
Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer (2006) 1.78
CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest (2011) 1.71
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2013) 1.66
A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. Am J Physiol Renal Physiol (2010) 1.63
Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A (2002) 1.51
Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol (2008) 1.42
Grade-dependent proteomics characterization of kidney cancer. Mol Cell Proteomics (2009) 1.41
Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther (2011) 1.30
Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol (2003) 1.25
Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS (2011) 1.23
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Mol Cancer Ther (2009) 1.22
Urinary acylcarnitines are altered in human kidney cancer. Int J Cancer (2011) 1.14
Urine metabolomics for kidney cancer detection and biomarker discovery. Urol Oncol (2011) 1.12
p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels. BMC Nephrol (2007) 1.11
An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells. Mol Cancer Ther (2003) 1.11
Individual variation in lipidomic profiles of healthy subjects in response to omega-3 Fatty acids. PLoS One (2013) 1.10
Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations. Metabolomics (2012) 1.09
New opportunities from the cancer metabolome. Clin Chem (2012) 1.06
High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers. Cancer Biol Ther (2008) 1.03
Cytosolic p21Waf1/Cip1 increases cell cycle transit in vascular smooth muscle cells. Cell Signal (2004) 1.03
Stability of miRNA in human urine supports its biomarker potential. Biomark Med (2013) 1.02
Anti-inflammatory effects of ω-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J Cardiovasc Pharmacol (2013) 0.99
BMP-2 inhibits proliferation of human aortic smooth muscle cells via p21Cip1/Waf1. Am J Physiol Endocrinol Metab (2003) 0.98
Urine dipstick analysis for identification of runners susceptible to acute kidney injury following an ultramarathon. J Sports Sci (2012) 0.94
Potential biofluid markers and treatment targets for renal cell carcinoma. Nat Rev Urol (2013) 0.91
Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Mol Cancer (2007) 0.91
Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53. J Urol (2008) 0.89
Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition. J Pharmacol Exp Ther (2005) 0.89
Inhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells. PLoS One (2013) 0.86
Rapid and quantitative DNA analysis of genetic mutations for polycystic kidney disease (PKD) using magnetic/luminescent nanoparticles. Anal Bioanal Chem (2008) 0.86
A novel p21 attenuator which is structurally related to sorafenib. Cancer Biol Ther (2013) 0.83
Exercise-associated hyponatremia with exertional rhabdomyolysis: importance of proper treatment. Clin Nephrol (2015) 0.81
Targeting the PI3K-Akt pathway in kidney cancer. Expert Rev Anticancer Ther (2007) 0.81
Disparate effects of roscovitine on renal tubular epithelial cell apoptosis and senescence: implications for autosomal dominant polycystic kidney disease. Am J Nephrol (2008) 0.79
Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma. J Urol (2010) 0.79
Effects of imputation on correlation: implications for analysis of mass spectrometry data from multiple biological matrices. Brief Bioinform (2016) 0.79
Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21. AIDS (2016) 0.78
Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer. Future Med Chem (2013) 0.77
Overexpression of p73 causes apoptosis in vascular smooth muscle cells. Am J Physiol Cell Physiol (2002) 0.77
TNF-alpha-mediated apoptosis in vascular smooth muscle cells requires p73. Am J Physiol Cell Physiol (2005) 0.77
Biological evaluation of a novel sorafenib analogue, t-CUPM. Cancer Chemother Pharmacol (2014) 0.77
Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB. Anticancer Drugs (2014) 0.76
Does Acute Kidney Injury From an Ultramarathon Increase the Risk for Greater Subsequent Injury? Clin J Sport Med (2016) 0.75
From bead to flask: Synthesis of a complex β-amido-amide for probe-development studies. Beilstein J Org Chem (2013) 0.75
Applications of metabolomics for kidney disease research: from biomarkers to therapeutic targets. Organogenesis (2013) 0.75
Biomarkers in IgA nephropathy. Biomark Med (2014) 0.75